Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02798341 · ClinicalTrials.gov registry record
The Breast Program - Translational Cancer Resource
A clinical trial of Breast Cancer, sponsored by Abramson Cancer Center at Penn Medicine.
- Active
- Registry status
- 4,000
- Enrollment target
- 1
- Study location
NCT02798341: Active study of Breast Cancer, sponsored by Abramson Cancer Center at Penn Medicine.
NCT02798341 is a study of Breast Cancer that is active but no longer recruiting, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 4,000 participants, above the 2,800-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (43% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02798341, a study of Breast Cancer, is active but no longer recruiting, sponsored by Abramson Cancer Center at Penn Medicine.
- ACTIVE NOT RECRUITING
- Registry status
- 4,000 participants
- Enrollment target
- 1
- Study location
Study Summary
TRACR will provide a data/biospecimen repository for translational research to better diagnose, prognose, treat and cure breast cancer (and related diseases/treatment conditions). Patients at the Rowan Breast Center will be consented for donation of blood and if available tumor/healthy/archived tissue. Patients will be consented to give permission to use said specimens for future research and to be contacted in the future about other research participation and additional information.
Conditions Studied
Interventions
- OTHER Biospecimen Collection
Study Locations (1)
Pennsylvania
- Abramson Cancer Center of the University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,000 participants |
| Start Date | 2012-07 |
| Est. Completion | 2030-07 |
What the registry record for NCT02798341 still lists
NCT02798341 is an observational study that tracks outcomes without assigning an intervention. Its 4,000 participants enrollment target places it among the larger protocols in the corpus, above the 2,800-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (43% higher).
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Biospecimen Collection is the first listed.
NCT02798341 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT02798341 about?
NCT02798341 is a clinical study titled "The Breast Program - Translational Cancer Resource". TRACR will provide a data/biospecimen repository for translational research to better diagnose, prognose, treat and cure breast cancer (and related diseases/treatment conditions). Patients at the Rowan Breast Center will be consented for donation of blood and if available tumor/healthy/archived tiss...
What is the current status of trial NCT02798341?
This trial is currently active not recruiting. The enrollment target is 4,000 participants. The study started on 2012-07. Estimated completion is 2030-07.
What conditions does trial NCT02798341 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT02798341?
The interventions under investigation include: Biospecimen Collection (OTHER).
Who is sponsoring clinical trial NCT02798341?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02798341 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02798341's enrollment target sits among peer trials
4,000 36th of 1224 higher than 1,188 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Surviving Daily Life
RECRUITING
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
UNC Pleural Fluid Registry
RECRUITING
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00227253 · 4,000 participants
Chromosome 18 Clinical Research Center
- NCT00811148 · 4,000 participants
Florida Center for Brain Tumor Research
- NCT00897117 · 4,000 participants
Collecting and Analyzing Tissue Samples From Patients Undergoing Surgery for Non-Small Cell Lung Cancer
- NCT01399385 · 4,000 participants · NA
New Heart Imaging Techniques to Evaluate Possible Heart Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia